Alps Advisors Inc Zymeworks Inc. Transaction History

Alps Advisors Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 09, 2022	SELL	$15.19 - $29.33 $863,566 - $1.67 Million	-56,851 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$27.35 - $37.28 $97,420 - $132,791	-3,562 Reduced 5.9%	56,851 $1.65 Million
Q2 2021 Aug 11, 2021	SELL	$26.5 - $38.23 $601,921 - $868,356	-22,714 Reduced 27.32%	60,413 $2.1 Million
Q1 2021 May 07, 2021	BUY	$29.83 - $56.81 $19,598 - $37,324	657 Added 0.8%	83,127 $2.63 Million
Q4 2020 Feb 03, 2021	BUY	$39.12 - $54.99 $950,185 - $1.34 Million	24,289 Added 41.75%	82,470 $3.9 Million
Q3 2020 Nov 04, 2020	SELL	$29.21 - $46.58 $115,058 - $183,478	-3,939 Reduced 6.34%	58,181 $2.71 Million
Q2 2020 Aug 05, 2020	SELL	$33.67 - $40.0 $620,874 - $737,600	-18,440 Reduced 22.89%	62,120 $2.24 Million
Q1 2020 May 06, 2020	BUY	$24.28 - $49.8 $31,636 - $64,889	1,303 Added 1.64%	80,560 $2.86 Million
Q4 2019 Feb 07, 2020	BUY	$24.84 - $45.46 $1.97 Million - $3.6 Million	79,257 New	79,257 $3.6 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $872M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.